Glargine, a new long-acting insulin analog for diabetic cats

Journal of Veterinary Internal Medicine

Volumn 20, Issue 2, 2006, Pages 219-220

  Rand, Jacquie ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLARGINE; INSULIN;

ANIMAL; ANIMAL DISEASE; CAT; CAT DISEASE; DIABETES MELLITUS; EDITORIAL;

ANIMALS; CAT DISEASES; CATS; DIABETES MELLITUS; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 33645558708     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2006)20[219:EGANLI]2.0.CO;2     Document Type: Editorial

References (5)

1. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000;49:2142-2148.
2. Evans ML, Keshavarz T, Flanagan DV, et al. ICV brain glibenclamide suppresses counterregulatory responses to brain glucopenia in rats: Evidence for a role for brain KATP channels in hypoglycemia sensing. Program and Abstracts of the 62nd Scientific Sessions of the American Diabetes Association, June 14-18, 2002, San Francisco, CA. Diabetes 51(Suppl 2):Abstract 293-OR.
3. Marshall R, Rand J. Treatment with insulin glargine results in higher remission rates than lente or protamine zinc insulins in newly diagnosed diabetic cats. Proceedings of the 23rd American Veterinary Internal Medicine Forum, 2005.
4. Marshall R, Rand J. Comparison of the pharmacokinetics and pharmacodynamics of once versus twice daily administration of insulin glargine in normal cats. Proceedings of the 20th American Veterinary Internal Medicine Forum, Dallas, TX, 2002.
5. Ratner RE, Hirsch I, Neifing J, et al. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care 2000;23:639-643.